{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-035514","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2025-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.867262+00:00","generated_at":"2026-05-16T18:48:34.627852+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Genprex granted US patent for REQORSA plus PD-L1 antibody combo through 2037","bullets":["USPTO patent covers REQORSA gene therapy combined with PD-L1 antibodies like Tecentriq, securing exclusivity to 2037.","Patents now granted in US and Korea; applications pending in Europe, Canada, Brazil, China, Israel.","Acclaim-3 Phase 1/2 trial for ES-SCLC combines REQORSA with Genentech's Tecentriq; Phase 2 expansion to enroll ~50 patients.","Interim analysis planned after 25th patient reaches 18 weeks; enrollment completion expected first half 2026.","Acclaim-3 has FDA Fast Track and Orphan Drug designations."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-035514","json":"https://secwatch.observer/filing/0001437749-25-035514.json","markdown":"https://secwatch.observer/filing/0001437749-25-035514.md","text":"https://secwatch.observer/filing/0001437749-25-035514.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925035514/0001437749-25-035514-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925035514/gnpx20251116_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T18:48:34.627852+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}